A recent study from the From the Department of Surgery, University of Pittsburgh Cancer Institute, Division of Pediatric Surgery, Children’s Hospital Pittsburgh, Department of Pharmacology and Chemical Biology, and Vascular Medicine Institute, University of Pittsburgh School of Medicine, PA, USA shows that “Genetic deletion of toll-like receptor 4 on platelets attenuates experimental pulmonary hypertension.” This study was published in the 9 May 2014 issue of the Journal Circulation Research [I.F:>10.00] by Drs. Bauer PM, Bauer EM and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: MiRNA-based therapy for pulmonary hypertension: RKIP stifles pulmonary hypertension via down regulation of its target gene. This study suggests, for the first time, that RKIP, by decreasing the expression of its target gene, may decrease: (1) Right ventricular systolic pressure, (2) Right ventricular hypertrophy, and (3) pulmonary vascular remodeling. Together, pharmacological formulations encompassing “RKIP activators” may be used to treat patients suffering from pulmonary hypertension.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, MiRNA-based therapy for pulmonary hypertension: RKIP stifles pulmonary hypertension via down regulation of its target gene, 26/March/2015, 22.29, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at email@example.com
* Research cooperation
Undisclosed information: How RKIP stifles pulmonary hypertension